Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
According to Anteris, the funds will be directed toward the company’s next stage of growth, including recruitment for the DurAVR Transcatheter Heart Valve (THV) global pivotal trial for patients with aortic stenosis, execution of its clinical strategy, and expansion of manufacturing capabilities.
In an ASX announcement, the company said the proceeds will also fund ongoing research and development activities for v2vmedtech, inc, alongside working capital and other corporate purposes.
Anteris noted that strategic capital deployment will be used to strengthen its manufacturing infrastructure, including establishing diversified ADAPT tissue sourcing channels in the United States and Australia to reduce supply chain dependencies and enhance production resilience.
The company said the offering received backing from existing shareholders including L1 Capital, Sio Capital, Nantahala Capital Management, ADAR1 Capital Management, and Rhenman & Partners Asset Management, with new investor Second Line Capital Management LLC also joining the round.
Anteris said the expansion of manufacturing capacity and regulatory clearances are key milestones as it prepares for further clinical trial developments across the United States, Europe, and Canada.
Settlement of the US offer and issuance of shares and warrants took place on 27 October (US time), with the Australian offer scheduled to settle on 30 October.
Trading of new CDIs on the ASX is anticipated on or before 7 November 2025, subject to confirmation from the exchange.
Evolution Capital Pty Ltd acted as sole lead manager for the placement.
The content of this article is based on information supplied by Anteris Technologies Global Corp. For more information, please refer to the official company announcement and communications from Anteris. Please consult a licensed and/or registered professional in this area before making any decisions based on the content of this article.
